The US market for personalised medicine is worth $232bn and is expected to grow by 11% annually, according to a report.
The PricewaterhouseCoopers (PwC) report said that the market will grow to $452bn by 2015.
Personalised medicine targets individualised treatment and care based on personal and genetic variation and is creating a booming market.
The core diagnostic and therapeutic segment of the market is comprised primarily of pharmaceutical, medical device and diagnostics companies and is estimated at $24bn.
This sector is expected to grow by 10% annually, reaching $42bn by 2015.